Search

Your search keyword '"Khachatryan, Naira"' showing total 5 results
Start Over Author "Khachatryan, Naira" Search Limiters Full Text Topic antitubercular agents
5 results on '"Khachatryan, Naira"'

1. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.

Author

Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, Fréchet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schünemann HJ, and Lienhardt C

Subjects
Adult, Antitubercular Agents pharmacology, Cohort Studies, Diarylquinolines pharmacology, Drug Resistance, Multiple, Bacterial, Extensively Drug-Resistant Tuberculosis drug therapy, Extensively Drug-Resistant Tuberculosis microbiology, Female, Humans, Male, Middle Aged, Odds Ratio, Treatment Outcome, Young Adult, Antitubercular Agents therapeutic use, Diarylquinolines therapeutic use, Mycobacterium tuberculosis drug effects, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant microbiology
Abstract

Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%-81.9%), and the treatment success rate was 65.8% (95% CI 59.9%-71.3%). Death rate was 11.7% (95% CI 7.0%-19.1%). Up to 91.1% (95% CI 82.2%-95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%-23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.

Published
2019
Full Text
View/download PDF

2. Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?

Author

Bastard M, Guglielmetti L, Huerga H, Hayrapetyan A, Khachatryan N, Yegiazaryan L, Faqirzai J, Hovhannisyan L, Varaine F, and Hewison C

Subjects
Adult, Armenia, Cohort Studies, Female, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Antitubercular Agents therapeutic use, Diarylquinolines therapeutic use, Fluoroquinolones, Tuberculosis, Multidrug-Resistant drug therapy
Published
2018
Full Text
View/download PDF

3. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.

Author

Tadolini M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, Centis R, Schaaf HS, Marais BJ, Ferreira H, Caminero JA, Jonckheere S, Sinha A, Herboczek K, Khaidarkhanova Z, Hayrapetyan A, Khachatryan N, Urtkmelidze Ia, Loreti C, Esposito S, Matteelli A, Furin J, Varaine F, and Migliori GB

Subjects
Adolescent, Child, Extensively Drug-Resistant Tuberculosis diagnosis, Female, Humans, Male, Treatment Outcome, Antitubercular Agents therapeutic use, Compassionate Use Trials, Extensively Drug-Resistant Tuberculosis drug therapy
Abstract

Competing Interests: Conflicts of Interest: None declared.

Published
2016
Full Text
View/download PDF

4. Availability and costs of medicines for the treatment of tuberculosis in Europe

Author

Günther, Gunar, Guglielmetti, Lorenzo, Leu, Claude, Lange, Christoph, van Leth, Frank, Hafizi, Hasan, Khachatryan, Naira, Aroyan, Harut, Kabasakalyan, Eduard, Knappik, Michael, Skrahina, Alena, Klimuk, Dzmitry, Nikolenka, Alena, Muylle, Inge, Milanov, Vladimir, Velkovska, Desislava, Tarinska, Neli, Bachiyska, Elizabeta, Jankovic, Mateja, Pieridou, Despo, Adamide, Tonia, Nicolaou, Nicos, Vasakova, Martina, Sukholytka, Mariia, Kopeckà, Emilia, Andersen, Åse Bengård, Folkvardsen, Dorte Bek, Svensson, Erik, Danilovits, Manfred, Kummik, Tiina, Vasankari, Tuula, Fréchet-Jachym, Mathilde, Nahmiash, Audrey, Togonidze, Tamar, Avaliani, Zaza, Kinkladze, Inga, Aspindzelashvili, Rusudan, Bichashvili, Teona, Losaberidze, Gulnazi, Merabishvili, Tsitsino, Kalsdorf, Barbara, Manika, Katerina, Tsiakitzis, Karyofyllis, Bakos, Agnes, Ægisdóttir, Tinna Rán, Michelsen, Guðrún Svanhvít, Karlsdóttir, Kristín, McLaughlin, Anne-Marie, Fitzgibbon, Margaret, Chemtob, Daniel, Codecasa, Luigi R., Ferrarese, Maurizio, Torri, Stefania, Gjocaj, Majlinda, Kuksa, Liga, Davidaviciene, Edita, Wirtz, Gil, Perrin, Monique, Asciak, Analita Pace, Chesov, Dumitri, de Lange, Wiel, Akkerman, Onno, Poposka, Biljana Ilievska, Mack, Ulrich, Jensenius, Mogens, Kvalvik, Lajla, Mengshoel, Anne Torunn, Kruczak, Katarzyna, Duarte, Raquel, Ribeiro, Nadine, Ibraim, Elmira, Kaluzhenina, Anna, Barkanova, Olga, Pesut, Dragica, Solovic, Ivan, Svetina, Petra, Souza-Galvão, Maria-Luiza de, Millet, Joan-Pau, Casas, Xavi, Vives, Montserrat, Bruchfeld, Judith, Dalemo, Paulina, Jonsson, Jerker, Aeschbacher, Katrin, Keller, Peter, Özkara, Seref, Tiberi, Simon, Chen, Christabelle, Terleeva, Yana, Dudnyk, Andrii, Health Economics and Health Technology Assessment, APH - Global Health, APH - Methodology, and Microbes in Health and Disease (MHD)

Subjects
Microbiology (medical), Evropa, Extensively Drug-Resistant Tuberculosis, Antitubercular Agents, Capacity building, 610 Medicine & health, MDR-TB, Mycobacterium tuberculosis - terapija z zdravili, Microbial Sensitivity Tests, Antimicrobial resistance, Medicines, Mycobacterium tuberculosis - drug therapy, SDG 3 - Good Health and Well-being, Tuberculosis, Multidrug-Resistant, Humans, Tuberculosis, tuberkuloza - terapija z zdravili, health care costs - drug therapy, Mycobacterium tuberculosis, General Medicine, END-TB strategy, udc:616-002, tuberculosis - drug therapy, Costs, stroški zdravstvene oskrbe - terapija z zdravili, Europe, Infectious Diseases, Availability of medicines
Abstract

Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries.Methods: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries.Results: Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as follows: (a) 75% (30/40) for levofloxacin, (b) 82% (33/40) for moxifloxacin, (c) 48% (19/40) for bedaquiline, and (d) 72% (29/40) for linezolid. Overall, of the 43 countries, 36 (84%) and 24 (56%) countries had access to bedaquiline and delamanid, respectively, whereas only 6 (14%) countries had access to rifapentine. The treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was available only in 17 (40%) of the 43 countries. The median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for 6 months), and extensively drug-resistant tuberculosis (including bedaquiline, delamanid, and a carbapenem) were €44 (minimum–maximum, €15–152), €764 (minimum–maximum, €542–15152), and €8709 (minimum–maximum, €7965–11759) in middle-income countries (n = 12) and €280 (minimum–maximum, €78–1084), €29765 (minimum–maximum, €11116–40584), and €217591 (minimum–maximum, €82827–320146) in high-income countries (n = 29), respectively.Discussion: In countries of the WHO European region, there is a widespread lack of drug susceptibility testing capacity to new and repurposed antituberculosis drugs, lack of access to essential medications in several countries, and a high cost for the treatment of drug-resistant tuberculosis.

Published
2023

5. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges

Author

Rosella Centis, Jose A. Caminero, Alberto Matteelli, Naira Khachatryan, Animesh Sinha, Jennifer Furin, Sylvie Jonckheere, Anthony J. Garcia-Prats, Hannetjie Ferreira, Catherine Hewison, Zarema Khaidarkhanova, Giovanni Battista Migliori, Susanna Esposito, Armen Hayrapetyan, Ia Urtkmelidze, H. Simon Schaaf, Ben J. Marais, Marina Tadolini, Carolina V Loreti, Krzysztof Herboczek, Lia D'Ambrosio, Francis Varaine, Tadolini, Marina, Garcia-Prats, Anthony J., D'Ambrosio, Lia, Hewison, Catherine, Centis, Rosella, Schaaf, H. Simon, Marais, Ben J., Ferreira, Hannetjie, Caminero, Jose A., Jonckheere, Sylvie, Sinha, Animesh, Herboczek, Krzysztof, Khaidarkhanova, Zarema, Hayrapetyan, Armen, Khachatryan, Naira, Urtkmelidze, Ia, Loreti, Carolina, Esposito, Susanna, Matteelli, Alberto, Furin, Jennifer, Varaine, Franci, and Migliori, Giovanni Battista

Subjects
Compassionate Use Trials, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Pediatrics, Adolescent, Extensively Drug-Resistant Tuberculosis, Treatment outcome, Antitubercular Agents, Alternative medicine, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, 030212 general & internal medicine, Child, Intensive care medicine, Agora, business.industry, Compassionate Use, Extensively drug-resistant tuberculosis, medicine.disease, Research Letters, Multiple drug resistance, Treatment Outcome, 030228 respiratory system, Pulmonary and Respiratory Medicine, children, Female, business
Abstract

The World Health Organization (WHO) estimated that 480 000 new multidrug-resistant (MDR) tuberculosis (TB) cases occurred globally in 2014, with 190 000 deaths. Limited data are available on the burden of MDR-TB in children. A recent systematic review estimated that 32 000 children acquire MDR-TB annually; of these, very few are correctly diagnosed and provided with appropriate treatment [1]., First experience and challenges of compassionate use of new anti-TB drugs to treat MDR- and XDR-TB in children http://ow.ly/SWXF300a0UX

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results